Mutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?

Haematologica

Volumn 95, Issue 9, 2010, Pages 1616-

  Steinemann, Doris ^a   Tauscher, Marcel ^a   Praulich, Inka ^a   Niemeyer, Charlotte M ^b   Flotho, Christian ^b   Schlegelberger, Brigitte ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

JMML; Let 7; RAS pathway

Indexed keywords

K RAS PROTEIN; MESSENGER RNA; MICRORNA; PROTEIN LET 7; RAS PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL PROLIFERATION; ENZYME ACTIVATION; FAMILIAL CANCER; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LETTER; LEUKEMOGENESIS; LUNG NON SMALL CELL CANCER; MULTIGENE FAMILY; NONHUMAN; ONCOGENE;

BINDING SITES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MICRORNAS; MUTATION; RAS PROTEINS; UP-REGULATION;

EID: 77956802199     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.024984     Document Type: Letter

References (12)

1. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999; 106(4):1027-32.
2. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295-308.
3. Flotho C, Kratz C, Niemeyer CM. Targeting RAS signaling pathways in juvenile myelomonocytic leukemia. Curr Drug Targets. 2007;8(6):715-25.
4. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114(9):1859-63.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66.
6. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6.
7. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635-47.
8. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753-6.
9. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68(20):8535-40.
10. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9(6):435-43.
11. Shen J, DiCioccio R, Odunsi K, Lele S, Zhao H. Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer. 2010;10(1):47.
12. Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet. 2009;46(5):358-60.